| Bailey Aleece Norton, | |
|
2070 Mckenzie Rd Ste C, Springdale, AR 72762-0870 | |
| (479) 750-7778 | |
| Not Available |
| Full Name | Bailey Aleece Norton |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 2070 Mckenzie Rd Ste C, Springdale, Arkansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013640168 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 201813 (Arkansas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Bailey Aleece Norton, 395 N Drewrys Bluff Dr, Fayetteville, AR 72704-7103 Ph: (479) 530-7426 | Bailey Aleece Norton, 2070 Mckenzie Rd Ste C, Springdale, AR 72762-0870 Ph: (479) 750-7778 |
News Archive
Reproductive health experts at the Centers for Disease Control and Prevention (CDC) have launched three new online videos to provide science-based information for anyone considering Assisted Reproductive Technology (ART).
Desperate times need desperate measures. Accordingly, scientists, today published a new study in the journal Cell Host and Microbe in March 2020, showing that drugs that prevent the acquisition of DNA-borne antibiotic resistance traits from their surroundings by bacteria can stop mice from becoming resistant to the action of the antibiotics.
Alkermes plc today announced positive topline results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia. Patients treated once monthly with either 441 mg or 882 mg of aripiprazole lauroxil demonstrated statistically significant reductions from baseline in Positive and Negative Syndrome Scale (PANSS) total scores at week 12, compared to placebo (p<0.001 aripiprazole lauroxil 441 mg, p<0.001 aripiprazole lauroxil 882 mg), which was the prespecified primary endpoint in the study. Based on the positive results from this phase 3 study, Alkermes plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the third quarter of 2014.
Jennerex, Inc., a clinical-stage biotherapeutics company developing a proprietary breakthrough class of targeted oncolytic virus therapeutics, today announced in conjunction with Lee's Pharmaceutical Holdings, the execution of a collaboration and license agreement for Jennerex's lead product candidate, JX-594, in certain Asian territories.
The first detailed search of breast cancer genomes to uncover genomic rearrangements is published today. The team characterised the ways in which the human genome is broken and put back together in 24 cases of breast cancer.
› Verified 4 days ago
Lauren Mariah Dixon, CF-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 956 Mathias Dr, Springdale, AR 72762 Phone: 479-419-9911 | |
Christa Griffith, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2210 Main Dr, Springdale, AR 72762 Phone: 479-856-6397 | |
Makenna Marie Sisson, MCD, CFY-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 6815 Isaacs Orchard Rd Ste D, Springdale, AR 72762 Phone: 479-856-6400 | |
Kathryn Michelle Cochran, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3917 S Old Missouri Rd, Springdale, AR 72764 Phone: 479-872-1800 Fax: 479-872-4654 | |
Ms. Sarah Elizabeth Dennis, MS Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 105 S Blair St, Springdale, AR 72764 Phone: 479-200-6795 | |
Tara Ray Wright, MS CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 105 S Blair St, Springdale, AR 72764 Phone: 479-259-2339 Fax: 479-751-4000 |